Bone Density clinical trials at UCSF

1 research study open to eligible people

Bone density is the amount of mineral in a bone that helps it stay firm. UCSF is testing a drug in an early phase study for solid tumors that come back or do not respond. The study measures the safest dose, side effects, and any signs of benefit.

Showing trials for

  • Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    open to eligible people ages 12 months to 30 years

    This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.

    San Francisco, California and other locations

Our lead scientists for Bone Density research studies include .

Last updated: